Key result
Aspirin exposure after colorectal cancer diagnosis was independently associated with improved colorectal cancer-specific survival (HR 0.85; 95% CI 0.79-0.92).
Why the study?
Does aspirin exposure after diagnosis improve colorectal cancer-specific survival and overall survival in patients with colorectal cancer?
Population
23,162 patients diagnosed with colorectal cancer (CRC) from 2004 through 2011 in Norway.
Comparison
Aspirin exposure, defined as receipt of aspirin… vs Unexposed patients.
Design
Cohort
Follow-up
median 3.0 years
Authors
Loading...
Post-diagnosis aspirin use was associated with improved CRC survival; leaves open a role for secondary prevention pending randomized trials.
Cohort (n=23,162)
Does aspirin exposure after diagnosis improve colorectal cancer-specific survival and overall survival in patients with colorectal cancer?
Hazard Ratio: 0.85 (95% CI 0.79–0.92)
Absolute Event Rate: 19% vs 31.5%
Aspirin use for more than 6 months after a colorectal cancer diagnosis is associated with improved colorectal cancer-specific and overall survival.
Bains et al. (2016) conducted a cohort in Colorectal cancer (n=23,162). Aspirin vs. Unexposed patients was evaluated on Colorectal cancer-specific survival (CSS) (HR 0.85, 95% CI 0.79-0.92). Aspirin exposure after colorectal cancer diagnosis was independently associated with improved colorectal cancer-specific survival (HR 0.85; 95% CI 0.79-0.92).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: